Gena Announces Partnership with CureGBM
· Gena Health Team
We are delighted to announce a new partnership between Gena Health and CureGBM, an organisation dedicated to advancing treatment access for brain tumour patients and their families.
CureGBM was founded by Richard Wakefield and Jane Oberholzer with the mission to improve outcomes for brain tumour patients through advancing innovations in sonodynamic therapy (SDT). CureGBM has also, in its own right, become a powerful voice within the GBM community, championing awareness, supporting patients and families through diagnosis, and advocating for access to emerging treatments. Their patient-centred mission and tireless advocacy align closely with what Skomer and Rob have built at Gena Health.
"We're excited to partner with Gena Health. Their clinical intelligence platform creates a direct pathway between patients and trials, which is essential as we scale our sonodynamic therapy programme across Europe. Access to treatment shouldn't depend on whether a patient happens to know that the right trial exists. CureGBM was founded because that pathway didn't exist when our father was diagnosed with glioblastoma. Working with Gena Health means we're building the infrastructure that connects not just GBM patients, but patients across cancer types, to the trials that could change their outcomes."
— Richard Wakefield, Founder, CureGBM
Through this collaboration, Gena Health will work alongside CureGBM to improve how patients and families discover and evaluate treatment pathways, including clinical trials and specialist care options. This includes supporting awareness of emerging approaches such as sonodynamic therapy, where access to up-to-date trial information can make a real difference. CureGBM will also have access to Gena Health's platform to receive patient enquiries and share educational resources with their community.
"We are thrilled to collaborating with Richard, Jane, and the whole CureGBM team as we continue to build tools that make precision cancer treatment options easier to understand, navigate and access. Richard and Jane share a similar story to mine, having also lost a parent to GBM. It’s incredibly inspiring to see all the work they are doing to make SDT a reality for patients across Europe, and we a delighted to help play a small role."
— Skomer Bennett-Clemmow, Gena Health CEO and Co-Founder
CureGBM’s trial programme is being run under the supervision of Professor Philippe Schucht, MD, Deputy Chief Physician and Head of Neuro-oncology at InselSpital Bern. Philippe Schucht is a leading neurosurgeon specialising in brain tumours for both adults and children. As Head of Neuro-Oncology at the University Hospital Bern, he is known for championing innovation for brain tumour patients; having led numerous clinical trials, and been a founder of multiple medical companies — always with the goal of improving prognosis and preserving quality of life for patients.
About Gena Health
Gena Health is an agentic workspace for oncology healthcare providers managing complex cancer cases. It brings fragmented clinical data, guidelines, trials, and literature into a single interface, enabling clinicians to identify options, make decisions, and act.
Through one natural language workflow, clinicians can search for relevant trials, interrogate evidence, draft referrals, and share treatment pathways directly with patients.
Gena is built to address two structural constraints in cancer care: fragmented information that limits effective clinical reasoning, and administrative burden that slows execution. The result is faster, more coordinated decision-making, and reduced friction in getting patients to the next step in their care.
Why Gena Health
In 2019, founder Skomer Bennett-Clemmow’s mother, Jana, was diagnosed with glioblastoma (GBM), an aggressive brain cancer. After exhausting standard treatment options in the UK, he became her full-time carer, assembling potential treatments across a fragmented global landscape. That work extended her life by a year.
Jana passed away in 2022. This experience shaped Gena’s mission: to ensure every patient can identify and access the best available treatment options, as quickly as possible. This is the principle that Gena is build on.
“Time is the most important currency in cancer care. Our aim is to equip clinicians and patients with tools that reduce fragmentation, improve decision-making, and accelerate access to treatments and thus improving patient outcomes.”
— Skomer Bennett-Clemmow, CEO and Co-Founder, Gena Health
About CureGBM
CureGBM was founded by Richard Wakefield and Jane Oberholzer to improve outcomes for brain tumour patients by advancing sonodynamic therapy (SDT).
Alongside its focus on innovation, CureGBM has become a leading voice within the GBM community, raising awareness, supporting patients and families through diagnosis, and advocating for access to emerging treatments.
This patient-centred approach and sustained advocacy closely align with the mission behind Gena Health.
Learn more: www.curegbm.co.uk
About Glioblastoma
Glioblastoma (GBM) is an aggressive form of brain cancer with limited treatment options and a median survival of approximately 15 months following diagnosis. Standard treatment typically involves surgery, radiotherapy, and chemotherapy, but recurrence is common and options narrow significantly after first-line care. Patients and families often face a fragmented landscape when searching for clinical trials, specialist centres, or emerging therapies. This is why organisations like CureGBM, and tools like Gena Health, play an important role in helping patients navigate their options and access the care they need.
About Sonodynamic Therapy
Sonodynamic therapy (SDT) is a non-invasive treatment approach that uses low-intensity ultrasound combined with a sensitising agent to target cancer cells. The therapy is being explored as a potential option for glioblastoma and other difficult-to-treat cancers, particularly where conventional approaches have limited efficacy. While still an emerging field, early research and clinical trials are underway to evaluate its safety and effectiveness. CureGBM has been a prominent advocate for advancing awareness and access to SDT for glioblastoma patients.
Read more about SDT: